LBA3 Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
Authors:
- 3 December 2023
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 34, S1467-S1468